2017 may become a very exciting year for Patricia Biasutto, sepofarsen captain. Her work, developing a novel RNA therapy for Leber congenital amaurosis 10, has progressed steadily. The team expects to start a first clinical trial this year.
There are currently around 160 people working at ProQR, but that wasn’t always the case. When Hee Lam Chan joined in 2013, she was only employee number six. As a result, she has seen the company grow and develop.
He is one of the founders of ProQR, but even long before that Gerard Platenburg was involved in the development of RNA therapies. Even so, after decades of working on them he still gets enthusiastic when talking about RNA.
… As an employer, we value a diverse workforce in which people are encouraged to develop themselves both personally and professionally. We … • 30 vacation days. • An annual performance bonus. • Stock options. • A premium-free pension plan. • A commuting …
Partnerships in our industry are very common as companies look to benefit from knowledge and resource sharing. In this blog we explore why companies, like ProQR, partner with other companies.
Today we are delighted to announce the further expansion of our collaboration with Lilly. Lilly is a leader in innovative RNA science, making them a great partner for our Axiomer technology.
… for our liver programs, driving the discovery and development of novel RNA-based drug candidates for chronic … Science, and the Chief Scientific Officer to identify and develop new opportunities, optimize our portfolio, and ensure scientific …
Bart Klein was at the forefront of ProQR's Axiomer® RNA editing technology development. This platform technology makes it possible to use the cells own machinery to reverse mutations that cause a genetic disease. Read the interview.
In June we caught up with our Lead Talent Acquisition, Silvia Catellani, to talk about ProQR, Pride, and driving an inclusive culture for present and future ProQRians.
